Uniwersyteckie Centrum Kliniczne
- Address
- Ul. Mariana Smoluchowskiego 17, 80-214 Gdansk, Poland
Immune System Diseases
At Uniwersyteckie Centrum Kliniczne in Gdansk, research in immune system diseases focuses on conditions such as myasthenia gravis and the prevention of Herpes Zoster in immunocompromised children and adolescents. These studies are designed to better understand treatment response, immune protection, and overall safety in younger patients.
- Evaluating new treatment options for generalized myasthenia gravis in children and adolescents
- Studying pediatric Herpes Zoster prevention in immunocompromised patients
- Assessing immune response and safety in pediatric populations
This area of research supports improved care for children with complex immune-related conditions, with a strong emphasis on therapy effectiveness and protection against infection.
Nervous System Diseases
Clinical trials in nervous system diseases at this site examine relapsing-remitting multiple sclerosis and spinal muscular atrophy, with the goal of improving treatment outcomes for pediatric patients. The work includes efforts to evaluate how well therapies are tolerated and how they affect disease control and functional development.
- Investigating treatment effects in relapsing-remitting multiple sclerosis
- Exploring therapy response in spinal muscular atrophy
- Supporting better disease management in children and adolescents
The research reflects a broad commitment to advancing care in pediatric neurology, especially for conditions that can significantly affect movement, strength, and long-term neurological health.
Musculoskeletal Diseases
Studies in musculoskeletal diseases at Uniwersyteckie Centrum Kliniczne are closely linked to disorders that affect muscle function and physical ability, particularly spinal muscular atrophy and myasthenia gravis. These trials aim to determine whether emerging therapies can improve strength, mobility, and everyday functioning in young patients.
- Examining therapies for muscle weakness and impaired movement
- Focusing on functional improvement in spinal muscular atrophy
- Assessing treatment benefit in myasthenia gravis
This research area helps clarify how new approaches may support better physical outcomes and quality of life for children living with neuromuscular conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 34 therapeutic areas and 15 of 635 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 609 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 135 by active trials.
- 1Merck Sharp & Dohme LLC26active
lock +134 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG56trials
lock +66 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Uniwersyteckie Centrum Kliniczne
lock Showing 1 of 588 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21197) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 635 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 62 | Unknown | 2016-02-02 | 2026-05-11 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.